| Value | ₹415.0 Cr |
|---|
BSE filing, NSE: SPANDANA. Summary written from the filing by ALFA Finder's alert engine.
Spandana Sphoorty Financial Ltd: key numbers
- Share price
- ₹189.06
- Market cap
- ₹1,512 Cr
- Revenue (annual)
- ₹1,024 Cr
- Net profit (annual)
- ₹-699.1 Cr
- P/E (TTM)
- -4.6×Sector 19.8×
- Promoter holding
- 48.16%+0.00% QoQ
- FII holding
- 17.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Spandana Sphoorty Financial Ltd
All →Spandana Sphoorty Financial Earnings Call Transcript: Key Takeaways
Spandana shows operational recovery with AUM crossing ₹5,000 Cr, but masks stress via ARC sales.
Spandana Sphoorty Financial Other Announcement
CARE's quarterly monitoring report found no deviation in Spandana's rights issue proceeds. No proceeds were utilised during the quarter, with funds held in escrow.
- Execution
- Issue period August 01, 2025 to March 31, 2027
Spandana Sphoorty Financial Investor Presentation: Key Takeaways
Q2 FY27 PAT ₹18 Cr (PBT ₹37 Cr) on AUM ₹5,364 Cr (+10% QoQ). NIM rose to 13.6%, GNPA fell to 2.54%, and the turnaround continued.
Spandana Sphoorty Financial Results Update
Spandana Sphoorty reported Q2 FY27 PAT of Rs.18 Crore and PPOP of Rs.79 Crore in its press release. AUM rose 10% QoQ to Rs.5,364 Crore.
Spandana Sphoorty Financial Q2 FY27 Results: Turns Profitable, Net Profit ₹18.2 Cr
Spandana Sphoorty Financial Ltd reported revenue from operations of ₹324.9 Cr (+41.5% YoY) and net profit of ₹18.2 Cr for Q2 FY27.
- Key figure
- Net profit ₹18.2 Cr
Spandana Sphoorty Financial Debt & Borrowing: ₹0.49 Cr
Spandana paid ₹0.49 Crore of quarterly interest on its secured NCDs on 27 October 2026. The coupon rate is 10.75% on a ₹50 Crore issue.
- Value
- ₹0.49 Cr
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr